CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence

Kenro Hirata, Hidekazu Suzuki, H. Imaeda, Juntaro Matsuzaki, Hitoshi Tsugawa, Osamu Nagano, K. Asakura, Hideyuki Saya, T. Hibi

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

Background:Multiple early gastric cancers (EGCs) may develop in 6-14% of patients even after achieving curative endoscopic submucosal dissection (ESD); however, a useful biomarker for predicting recurrence is not available. The present study investigated whether the expression of CD44 variant 9 (CD44v9), a functional cancer stem cell marker, in the primary gastric cancer tissue represents an indicator of recurrence.Methods:Eighty-eight patients who underwent ESD for EGC from 2008 to 2010 were enrolled and monitored for recurrence for 3 years. The expression levels of CD44v9 in the tissue of initial EGCs were evaluated by immunohistochemistry, and the recurrence rate was compared between CD44v9-positive and CD44v9-negative groups. The mucin phenotype and expression of microRNA-21 (miR-21) and programmed cell death protein 4 (PDCD4) were also analysed.Results:The recurrence rate of EGC was significantly higher in the CD44v9-positive group than in the CD44v9-negative group (hazard ratio (HR), 21.8; 95% confidence interval (CI), 5.71-83.1). However, mucin phenotypes and the expression of miR-21 and PDCD4 did not predict recurrence after ESD. Meanwhile, grade of gastric atrophy was also identified as a significant marker of multiple recurrence (HR, 4.95; 95% CI, 1.30-18.8).Conclusion:CD44 variant 9 expression represents a potential predictive marker for recurrence in EGC.

Original languageEnglish
Pages (from-to)379-386
Number of pages8
JournalBritish Journal of Cancer
Volume109
Issue number2
DOIs
Publication statusPublished - 2013 Jul 23

Fingerprint

Stomach Neoplasms
Recurrence
Apoptosis Regulatory Proteins
Mucins
MicroRNAs
Confidence Intervals
Phenotype
Neoplastic Stem Cells
Atrophy
Stomach
Biomarkers
Immunohistochemistry
Endoscopic Mucosal Resection

Keywords

  • biomarker
  • cancer stem cell
  • CD44 variant 9
  • endoscopic procedure
  • gastric cancer
  • recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. / Hirata, Kenro; Suzuki, Hidekazu; Imaeda, H.; Matsuzaki, Juntaro; Tsugawa, Hitoshi; Nagano, Osamu; Asakura, K.; Saya, Hideyuki; Hibi, T.

In: British Journal of Cancer, Vol. 109, No. 2, 23.07.2013, p. 379-386.

Research output: Contribution to journalArticle

Hirata, Kenro ; Suzuki, Hidekazu ; Imaeda, H. ; Matsuzaki, Juntaro ; Tsugawa, Hitoshi ; Nagano, Osamu ; Asakura, K. ; Saya, Hideyuki ; Hibi, T. / CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence. In: British Journal of Cancer. 2013 ; Vol. 109, No. 2. pp. 379-386.
@article{acc8f35ef25f41ac80e5b9c807a3c459,
title = "CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence",
abstract = "Background:Multiple early gastric cancers (EGCs) may develop in 6-14{\%} of patients even after achieving curative endoscopic submucosal dissection (ESD); however, a useful biomarker for predicting recurrence is not available. The present study investigated whether the expression of CD44 variant 9 (CD44v9), a functional cancer stem cell marker, in the primary gastric cancer tissue represents an indicator of recurrence.Methods:Eighty-eight patients who underwent ESD for EGC from 2008 to 2010 were enrolled and monitored for recurrence for 3 years. The expression levels of CD44v9 in the tissue of initial EGCs were evaluated by immunohistochemistry, and the recurrence rate was compared between CD44v9-positive and CD44v9-negative groups. The mucin phenotype and expression of microRNA-21 (miR-21) and programmed cell death protein 4 (PDCD4) were also analysed.Results:The recurrence rate of EGC was significantly higher in the CD44v9-positive group than in the CD44v9-negative group (hazard ratio (HR), 21.8; 95{\%} confidence interval (CI), 5.71-83.1). However, mucin phenotypes and the expression of miR-21 and PDCD4 did not predict recurrence after ESD. Meanwhile, grade of gastric atrophy was also identified as a significant marker of multiple recurrence (HR, 4.95; 95{\%} CI, 1.30-18.8).Conclusion:CD44 variant 9 expression represents a potential predictive marker for recurrence in EGC.",
keywords = "biomarker, cancer stem cell, CD44 variant 9, endoscopic procedure, gastric cancer, recurrence",
author = "Kenro Hirata and Hidekazu Suzuki and H. Imaeda and Juntaro Matsuzaki and Hitoshi Tsugawa and Osamu Nagano and K. Asakura and Hideyuki Saya and T. Hibi",
year = "2013",
month = "7",
day = "23",
doi = "10.1038/bjc.2013.314",
language = "English",
volume = "109",
pages = "379--386",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - CD44 variant 9 expression in primary early gastric cancer as a predictive marker for recurrence

AU - Hirata, Kenro

AU - Suzuki, Hidekazu

AU - Imaeda, H.

AU - Matsuzaki, Juntaro

AU - Tsugawa, Hitoshi

AU - Nagano, Osamu

AU - Asakura, K.

AU - Saya, Hideyuki

AU - Hibi, T.

PY - 2013/7/23

Y1 - 2013/7/23

N2 - Background:Multiple early gastric cancers (EGCs) may develop in 6-14% of patients even after achieving curative endoscopic submucosal dissection (ESD); however, a useful biomarker for predicting recurrence is not available. The present study investigated whether the expression of CD44 variant 9 (CD44v9), a functional cancer stem cell marker, in the primary gastric cancer tissue represents an indicator of recurrence.Methods:Eighty-eight patients who underwent ESD for EGC from 2008 to 2010 were enrolled and monitored for recurrence for 3 years. The expression levels of CD44v9 in the tissue of initial EGCs were evaluated by immunohistochemistry, and the recurrence rate was compared between CD44v9-positive and CD44v9-negative groups. The mucin phenotype and expression of microRNA-21 (miR-21) and programmed cell death protein 4 (PDCD4) were also analysed.Results:The recurrence rate of EGC was significantly higher in the CD44v9-positive group than in the CD44v9-negative group (hazard ratio (HR), 21.8; 95% confidence interval (CI), 5.71-83.1). However, mucin phenotypes and the expression of miR-21 and PDCD4 did not predict recurrence after ESD. Meanwhile, grade of gastric atrophy was also identified as a significant marker of multiple recurrence (HR, 4.95; 95% CI, 1.30-18.8).Conclusion:CD44 variant 9 expression represents a potential predictive marker for recurrence in EGC.

AB - Background:Multiple early gastric cancers (EGCs) may develop in 6-14% of patients even after achieving curative endoscopic submucosal dissection (ESD); however, a useful biomarker for predicting recurrence is not available. The present study investigated whether the expression of CD44 variant 9 (CD44v9), a functional cancer stem cell marker, in the primary gastric cancer tissue represents an indicator of recurrence.Methods:Eighty-eight patients who underwent ESD for EGC from 2008 to 2010 were enrolled and monitored for recurrence for 3 years. The expression levels of CD44v9 in the tissue of initial EGCs were evaluated by immunohistochemistry, and the recurrence rate was compared between CD44v9-positive and CD44v9-negative groups. The mucin phenotype and expression of microRNA-21 (miR-21) and programmed cell death protein 4 (PDCD4) were also analysed.Results:The recurrence rate of EGC was significantly higher in the CD44v9-positive group than in the CD44v9-negative group (hazard ratio (HR), 21.8; 95% confidence interval (CI), 5.71-83.1). However, mucin phenotypes and the expression of miR-21 and PDCD4 did not predict recurrence after ESD. Meanwhile, grade of gastric atrophy was also identified as a significant marker of multiple recurrence (HR, 4.95; 95% CI, 1.30-18.8).Conclusion:CD44 variant 9 expression represents a potential predictive marker for recurrence in EGC.

KW - biomarker

KW - cancer stem cell

KW - CD44 variant 9

KW - endoscopic procedure

KW - gastric cancer

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=84881104793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881104793&partnerID=8YFLogxK

U2 - 10.1038/bjc.2013.314

DO - 10.1038/bjc.2013.314

M3 - Article

C2 - 23778530

AN - SCOPUS:84881104793

VL - 109

SP - 379

EP - 386

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -